Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 12:11:637978.
doi: 10.3389/fonc.2021.637978. eCollection 2021.

Induction Chemotherapy Plus Simultaneous Modulated Accelerated Radiation Therapy in Non-operative Hypopharyngeal and Supraglottic Laryngeal Squamous Cell Carcinoma: Long-Term Outcome of a Prospective Phase 2 Study

Boning Cai  1 , Lingling Meng  1 , Jingzi Mo  2 , Shouping Xu  1 , Baolin Qu  1 , Fang Liu  1 , Lin Ma  1
Affiliations

Induction Chemotherapy Plus Simultaneous Modulated Accelerated Radiation Therapy in Non-operative Hypopharyngeal and Supraglottic Laryngeal Squamous Cell Carcinoma: Long-Term Outcome of a Prospective Phase 2 Study

Boning Cai et al. Front Oncol. .

Abstract

Background: To evaluate the toxicities and long-term outcomes of induction chemotherapy (ICT) plus simultaneous modulated accelerated radiation therapy (SMART) in non-operative hypopharyngeal and supraglottic laryngeal squamous cell carcinoma (SCCH/L). Materials and Methods: This was a prospective phase 2 study. Patients diagnosed with SCCH/L, aged from 18 to 75, staged from III to IVB in accordance with the AJCC 2010 criteria, and refusing surgery were eligible. The patients were treated with 2-3 cycles of docetaxel-cisplatin-based ICT and SMART combined with 2-3 cycles of cisplatin-based concurrent chemotherapy. The prescription dose to the primary tumor and metastatic nodes was 69 Gy in 30 fractions. Acute and late toxicities were assessed according to the established Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) criteria, and long-term outcomes were analyzed. Results: Between February 2013 and June 2015, 55 newly diagnosed SCCH/L patients were enrolled. No grade 2 or worse acute xerostomia was noted. The incidences of grade 3 acute dermatitis, oral mucositis, and pharyngoesophagitis were 12.7, 3.6, and 12.7%, respectively. The median follow-up time was 48 months (range 5.5-74 months). The main late toxicity was hoarseness or sore throat, with an incidence of 32.7%. The 5-year functional larynx-preservation survival was 51.5%. The 3- and 5-year locoregional control and overall survival were 58.2, 51.5, 63.6, and 54.1%, respectively. Conclusions: The ICT plus SMART with a regimen of 69 Gy/30 F for the treatment of SCCH/L demonstrated acceptable severe toxicity, satisfactory long-term outcomes, and laryngeal function preservation.

Keywords: chemoradiotherapy; hypopharynx; intensity-modulated radiotherapy; laryngeal neoplasms; squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Acute toxicities (n = 55).
Figure 2
Figure 2
Survival analysis: (A) locoregional control, (B) overall survival, and (C) functional larynx preservation.
Figure 3
Figure 3
Overall survival by tumor burden.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. (1996) 88:890–9. 10.1093/jnci/88.13.890 - DOI - PubMed
    1. Pignon JP, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. (2009) 92:4–14. 10.1016/j.radonc.2009.04.014 - DOI - PubMed
    1. Argiris A, Lefebvre JL. Laryngeal preservation strategies in locally advanced laryngeal and hypopharyngeal cancers. Front Oncol. (2019) 9:419. 10.3389/fonc.2019.00419 - DOI - PMC - PubMed
    1. Featherstone CJ, Clarke S, Jackson MA, Shannon KF, McNeil EB, Tin MM, et al. . Treatment of advanced cancer of the larynx and hypopharynx with chemoradiation. ANZ J Surg. (2004) 74:554–8. 10.1111/j.1445-2197.2004.03056.x - DOI - PubMed
    1. Paximadis P, Yoo G, Lin HS, Jacobs J, Sukari A, Dyson G, et al. . Concurrent chemoradiotherapy improves survival in patients with hypopharyngeal cancer. Int J Radiat Oncol Biol Phys. (2012) 82:1515–21. 10.1016/j.ijrobp.2011.04.064 - DOI - PMC - PubMed

LinkOut - more resources